July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

Biktarvy, Yescarta beat estimates
Gilead Sciences Inc. (NASDAQ:GILD) raised its 2019 sales guidance after reporting higher-than-expected 2Q19 earnings driven by sales of HIV drug Biktarvy bictegravir/emtricitabine/tenofovir alafenamide and CAR T therapy Yescarta axicabtagene ciloleucel. Biktarvy brought in $1.12 billion, up 505% from 2Q18, its first full quarter on the market, and ahead of consensus estimates of $974.1 million; Yescarta had sales of $120 million, up 76% year-over-year, and beating expectations of $112.9 million. Gilead reported EPS of $1.82 on revenues of $5.69 billion, beating analyst expectations of $1.72 and $5.53 billion, respectively. The company's 2Q18 figures were $1.91 and $5.65 billion, respectively.

Pfizer completes Array takeout
Pfizer Inc. (NYSE:PFE) said it has completed its acquisition of Array BioPharma Inc. (see "How Array Stayed Alive Long Enough to Grow Up")...